Cardiac & Hypertension

Adenosine Injection 6 mg per 2ml is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Amlodipine and Atenolol is a classic dual-mechanism cardiovascular combination pairing a dihydropyridine calcium channel blocker with a cardioselective beta-1 blocker. Amlodipine lowers peripheral vascular resistance and dilates coronary arteries, while atenolol reduces resting and exercise heart rates, suppresses cardiac contractility, and eliminates the reflex tachycardia typically triggered by dihydropyridine vasodilation. Indicated for essential hypertension and stable chronic angina pectoris.

Amlodipine (or S-Amlodipine, the pure chirally active enantiomer with lower incidence of ankle edema) is a third-generation dihydropyridine calcium channel blocker on the WHO Model List of Essential Medicines. It inhibits transmembrane influx of extracellular calcium ions into vascular smooth muscle and cardiac muscle through L-type channels, resulting in potent peripheral arterial and coronary vasodilation with an exceptionally long half-life (30-50 hours). Indicated for essential hypertension, chronic stable angina pectoris, and vasospastic (Prinzmetal's) angina.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).

HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).

Clonidine Tablets 100 mcg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Clopidogrel Bisulphate is an oral thienopyridine P2Y12 platelet inhibitor on the WHO Model List of Essential Medicines. It requires hepatic bioactivation by CYP2C19 to form an active thiol metabolite that irreversibly modifies platelet P2Y12 ADP receptors for the entire 7-10 day lifespan of the platelet, preventing ADP-induced platelet activation and fibrinogen binding. Indicated for secondary prevention of atherothrombotic events in patients with recent myocardial infarction, recent ischemic stroke, or established peripheral arterial disease, and as part of DAPT in acute coronary syndromes.

Clopidogrel and Aspirin is the cornerstone Dual Antiplatelet Therapy (DAPT) on the WHO Model List of Essential Medicines. Aspirin irreversibly acetylates platelet cyclooxygenase-1 (COX-1), blocking thromboxane A2 production, while clopidogrel is an oral thienopyridine prodrug whose active metabolite irreversibly binds to platelet P2Y12 adenosine diphosphate (ADP) receptors, preventing ADP-mediated glycoprotein IIb/IIIa activation. This dual blockade potently inhibits platelet aggregation across complementary pathways. Indicated for acute coronary syndromes (STEMI, NSTEMI, unstable angina) and prevention of subacute stent thrombosis following percutaneous coronary intervention (PCI).

Diltiazem Tablets 30 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Diltiazem Tablets 60 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Dobutamine Injection 250mg per 20ml (for Intravenous Infusion) is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Dopamine Hydrochloride Injection 200 mg per 5ml is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Angiotensin Converting Enzyme (ACE) Inhibitor on the WHO Model List of Essential Medicines. It blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, reducing peripheral arterial resistance, decreasing aldosterone secretion, and inhibiting the enzymatic degradation of bradykinin, producing potent vasodilation and cardioprotection. Indicated for essential hypertension, heart failure with reduced ejection fraction (HFrEF), post-myocardial infarction, and diabetic nephropathy.

Enoxaparin Injection 40 mg per 0.4 ml is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Enoxaparin Injection 60 mg per 0.6 ml is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Frusemide Injection 10 mg per ml is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Frusemide Tablets 40 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Heparin Sodium Injection 5000 IU is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Heparin Sodium Injection 25000 IU is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Isosorbide Dinitrate Tablets 10mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Amlodipine (or S-Amlodipine, the pure chirally active enantiomer with lower incidence of ankle edema) is a third-generation dihydropyridine calcium channel blocker on the WHO Model List of Essential Medicines. It inhibits transmembrane influx of extracellular calcium ions into vascular smooth muscle and cardiac muscle through L-type channels, resulting in potent peripheral arterial and coronary vasodilation with an exceptionally long half-life (30-50 hours). Indicated for essential hypertension, chronic stable angina pectoris, and vasospastic (Prinzmetal's) angina.

Angiotensin Converting Enzyme (ACE) Inhibitor on the WHO Model List of Essential Medicines. It blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, reducing peripheral arterial resistance, decreasing aldosterone secretion, and inhibiting the enzymatic degradation of bradykinin, producing potent vasodilation and cardioprotection. Indicated for essential hypertension, heart failure with reduced ejection fraction (HFrEF), post-myocardial infarction, and diabetic nephropathy.

Losartan Potassium and Hydrochlorothiazide combines a selective AT1 receptor blocker with a thiazide diuretic on the WHO Model List of Essential Medicines. Losartan blocks angiotensin II-induced vasoconstriction and uniquely possesses intrinsic uricosuric properties that increase uric acid excretion, offsetting the hyperuricemic tendency of hydrochlorothiazide, while hydrochlorothiazide reduces extracellular fluid volume. Indicated for the treatment of hypertension not adequately controlled on monotherapy and for reducing stroke risk in hypertensive patients with left ventricular hypertrophy.

Losartan Potassium is the prototype selective competitive angiotensin II receptor type 1 (AT1) antagonist on the WHO Model List of Essential Medicines. It blocks the physiological actions of angiotensin II, lowering systemic vascular resistance and aldosterone secretion, while its active metabolite EXP3174 provides long-acting non-competitive blockade. Possesses unique uricosuric activity, lowering serum uric acid levels. Indicated for essential hypertension, diabetic nephropathy in type 2 diabetes with elevated creatinine and proteinuria, and stroke reduction in hypertensive patients with left ventricular hypertrophy.

Losartan Potassium is the prototype selective competitive angiotensin II receptor type 1 (AT1) antagonist on the WHO Model List of Essential Medicines. It blocks the physiological actions of angiotensin II, lowering systemic vascular resistance and aldosterone secretion, while its active metabolite EXP3174 provides long-acting non-competitive blockade. Possesses unique uricosuric activity, lowering serum uric acid levels. Indicated for essential hypertension, diabetic nephropathy in type 2 diabetes with elevated creatinine and proteinuria, and stroke reduction in hypertensive patients with left ventricular hypertrophy.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Angiotensin Converting Enzyme (ACE) Inhibitor on the WHO Model List of Essential Medicines. It blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, reducing peripheral arterial resistance, decreasing aldosterone secretion, and inhibiting the enzymatic degradation of bradykinin, producing potent vasodilation and cardioprotection. Indicated for essential hypertension, heart failure with reduced ejection fraction (HFrEF), post-myocardial infarction, and diabetic nephropathy.

Angiotensin Converting Enzyme (ACE) Inhibitor on the WHO Model List of Essential Medicines. It blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, reducing peripheral arterial resistance, decreasing aldosterone secretion, and inhibiting the enzymatic degradation of bradykinin, producing potent vasodilation and cardioprotection. Indicated for essential hypertension, heart failure with reduced ejection fraction (HFrEF), post-myocardial infarction, and diabetic nephropathy.

Simvastatin Tablets 10mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Simvastatin Tablets 20mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Telmisartan and Hydrochlorothiazide combines an AT1 angiotensin II receptor antagonist with a thiazide diuretic. Telmisartan suppresses the renin-angiotensin-aldosterone axis, while hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted renal tubules, increasing urinary excretion of sodium, chloride, and water. Telmisartan counteracts diuretic-induced potassium wasting and metabolic disturbances. Indicated for the treatment of hypertension not adequately controlled on telmisartan monotherapy.

Telmisartan is a potent, non-peptide, long-acting angiotensin II type 1 (AT1) receptor antagonist on the WHO Model List of Essential Medicines. It exhibits an exceptionally long elimination half-life (around 24 hours) providing sustained 24-hour blood pressure control with high trough-to-peak ratio, and uniquely functions as a partial agonist at peroxisome proliferator-activated receptor-gamma (PPAR-gamma), improving glucose handling and lipid metabolism. Indicated for essential hypertension and cardiovascular risk reduction in patients with coronary artery disease, stroke, or diabetes with end-organ damage.

Telmisartan is a potent, non-peptide, long-acting angiotensin II type 1 (AT1) receptor antagonist on the WHO Model List of Essential Medicines. It exhibits an exceptionally long elimination half-life (around 24 hours) providing sustained 24-hour blood pressure control with high trough-to-peak ratio, and uniquely functions as a partial agonist at peroxisome proliferator-activated receptor-gamma (PPAR-gamma), improving glucose handling and lipid metabolism. Indicated for essential hypertension and cardiovascular risk reduction in patients with coronary artery disease, stroke, or diabetes with end-organ damage.

Tranexamic Acid Tablets 500 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Tranexamic Acid Injection 500 mg (100mg per ml) is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Atropine Sulphate Injection 0.6mg per ml is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Tranexamic Acid 500mg + Mefenamic Acid 250mg Tablets is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Selective alpha-1 adrenergic receptor antagonist. It competitively blocks post-junctional alpha-1 receptors on vascular smooth muscle, dilating both arterioles and veins to lower peripheral vascular resistance and systemic blood pressure, while also relaxing smooth muscle in the bladder neck and prostate capsule. Indicated for essential hypertension and benign prostatic hyperplasia (BPH).

Telmisartan and Amlodipine is a synergistic dual antihypertensive formulation. Telmisartan blocks vasoconstrictor and aldosterone-secreting effects of angiotensin II at AT1 receptors and improves insulin sensitivity via partial PPAR-gamma agonism, while amlodipine selectively inhibits transmembrane calcium influx in vascular smooth muscle, producing peripheral arteriolar vasodilation. Telmisartan post-capillary venodilation mitigates amlodipine-induced pre-capillary peripheral ankle edema. Indicated for essential hypertension in patients whose blood pressure is not adequately controlled on monotherapy.

HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).

Heparin Sodium 50IU + Benzyl Nicotinate 2mg Ointment is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Statin and Antiplatelet (Aspirin +/- Clopidogrel) cardiovascular polypill formulation. Unites intensive lipid lowering and plaque stabilization (via HMG-CoA reductase inhibition) with antiplatelet thrombus prevention (via irreversible COX-1 inhibition and/or ADP P2Y12 platelet receptor blockade). Indicated for secondary prevention in coronary artery disease, acute coronary syndrome, post-percutaneous coronary intervention (PCI/stenting), and ischemic stroke.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Torasemide is a high-ceiling loop diuretic of the pyridine-sulfonylurea class. It inhibits the Na+/K+/2Cl- luminal carrier in the thick ascending limb of Henle's loop, producing potent natriuresis and diuresis. Unlike furosemide, torasemide features high, predictable oral bioavailability (around 80%), a longer duration of action, and antialdosterone properties that decrease myocardial collagen accumulation. Indicated for edema associated with congestive heart failure, chronic renal failure, and hepatic cirrhosis, and for essential hypertension.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Diltiazem Sustained Release Tablets 90 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Acenocoumarol Tablets 2 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Amlodipine (or S-Amlodipine, the pure chirally active enantiomer with lower incidence of ankle edema) is a third-generation dihydropyridine calcium channel blocker on the WHO Model List of Essential Medicines. It inhibits transmembrane influx of extracellular calcium ions into vascular smooth muscle and cardiac muscle through L-type channels, resulting in potent peripheral arterial and coronary vasodilation with an exceptionally long half-life (30-50 hours). Indicated for essential hypertension, chronic stable angina pectoris, and vasospastic (Prinzmetal's) angina.

Digoxin is a purified cardiac glycoside extracted from Digitalis lanata on the WHO Model List of Essential Medicines. It reversibly inhibits the sarcolemmal Na+/K+-ATPase pump in cardiomyocytes, raising intracellular sodium and driving sodium-calcium exchange (NCX) to increase intracellular calcium, producing positive inotropic action (increased myocardial contractility). It also stimulates central vagal nuclei, slowing AV nodal conduction and ventricular rate. Indicated for heart failure with reduced ejection fraction and ventricular rate control in chronic atrial fibrillation.

Statin and Fenofibrate is a comprehensive dual-action lipid-regulating combination. The statin (Atorvastatin or Rosuvastatin) competitively inhibits HMG-CoA reductase, potently lowering LDL cholesterol and apolipoprotein B, while fenofibrate, a fibric acid derivative, activates peroxisome proliferator-activated receptor-alpha (PPAR-alpha), dramatically reducing triglycerides (by 30-50%), increasing HDL cholesterol, and converting atherogenic small dense LDL into larger buoyant particles. Indicated for mixed dyslipidemia, severe hypertriglyceridemia, and diabetic dyslipidemia.

Amiodarone Hydrochloride is a broad-spectrum Class III antiarrhythmic agent on the WHO Model List of Essential Medicines. It predominantly blocks voltage-gated potassium channels, prolonging myocardial action potential duration and effective refractory period across all cardiac tissues, while also exhibiting Class I (sodium channel block), Class II (antiadrenergic non-competitive beta-block), and Class IV (calcium channel block) actions. Features an enormous volume of distribution and an elimination half-life of 40 to 60 days. Indicated for life-threatening ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation) and supraventricular arrhythmias (atrial fibrillation/flutter).

Angiotensin Converting Enzyme (ACE) Inhibitor on the WHO Model List of Essential Medicines. It blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, reducing peripheral arterial resistance, decreasing aldosterone secretion, and inhibiting the enzymatic degradation of bradykinin, producing potent vasodilation and cardioprotection. Indicated for essential hypertension, heart failure with reduced ejection fraction (HFrEF), post-myocardial infarction, and diabetic nephropathy.

Olmesartan Medoxomil is a potent, orally active prodrug that is rapidly de-esterified during absorption to olmesartan, a selective and insurmountable competitive antagonist at the angiotensin II AT1 receptor. It produces profound, prolonged reductions in systemic vascular resistance and blood pressure throughout the 24-hour dosing interval. Indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents (amlodipine, cilnidipine, chlorthalidone, hydrochlorothiazide).

Isosorbide Mononitrate Sustained Release Tablets 30 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Statin and Fenofibrate is a comprehensive dual-action lipid-regulating combination. The statin (Atorvastatin or Rosuvastatin) competitively inhibits HMG-CoA reductase, potently lowering LDL cholesterol and apolipoprotein B, while fenofibrate, a fibric acid derivative, activates peroxisome proliferator-activated receptor-alpha (PPAR-alpha), dramatically reducing triglycerides (by 30-50%), increasing HDL cholesterol, and converting atherogenic small dense LDL into larger buoyant particles. Indicated for mixed dyslipidemia, severe hypertriglyceridemia, and diabetic dyslipidemia.

Telmisartan and Chlorthalidone is a potent, long-acting dual antihypertensive combination. Telmisartan delivers selective 24-hour AT1 receptor blockade, while chlorthalidone, a long-acting monosulfonamyl thiazide-like diuretic with a terminal elimination half-life of 40-60 hours, provides sustained intravascular volume and vascular resistance reduction throughout day and night. Indicated for stage 2 hypertension and nocturnal/early morning hypertension surges.

Nifedipine Prolonged release Tablets 20mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Indapamide is an indole-derivative thiazide-like chlorosulfamoyl diuretic and arterial vasodilator on the WHO Model List of Essential Medicines. At antihypertensive doses, it exhibits a dual mechanism: direct vascular action (stimulating prostaglandin PGE2 synthesis and blocking calcium influx in vascular smooth muscle to reduce peripheral resistance) combined with mild distal tubular natriuresis, exerting virtually neutral effects on lipids and glucose. Indicated for essential hypertension, alone or in fixed-dose combination with ACE inhibitors (perindopril) or CCBs.

Olmesartan Medoxomil is a potent, orally active prodrug that is rapidly de-esterified during absorption to olmesartan, a selective and insurmountable competitive antagonist at the angiotensin II AT1 receptor. It produces profound, prolonged reductions in systemic vascular resistance and blood pressure throughout the 24-hour dosing interval. Indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents (amlodipine, cilnidipine, chlorthalidone, hydrochlorothiazide).

Amlodipine (or S-Amlodipine, the pure chirally active enantiomer with lower incidence of ankle edema) is a third-generation dihydropyridine calcium channel blocker on the WHO Model List of Essential Medicines. It inhibits transmembrane influx of extracellular calcium ions into vascular smooth muscle and cardiac muscle through L-type channels, resulting in potent peripheral arterial and coronary vasodilation with an exceptionally long half-life (30-50 hours). Indicated for essential hypertension, chronic stable angina pectoris, and vasospastic (Prinzmetal's) angina.

Losartan Potassium is the prototype selective competitive angiotensin II receptor type 1 (AT1) antagonist on the WHO Model List of Essential Medicines. It blocks the physiological actions of angiotensin II, lowering systemic vascular resistance and aldosterone secretion, while its active metabolite EXP3174 provides long-acting non-competitive blockade. Possesses unique uricosuric activity, lowering serum uric acid levels. Indicated for essential hypertension, diabetic nephropathy in type 2 diabetes with elevated creatinine and proteinuria, and stroke reduction in hypertensive patients with left ventricular hypertrophy.

Fenofibrate Tablets 160 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Isosorbide Dinitrate Tablets 5 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Angiotensin Converting Enzyme (ACE) Inhibitor on the WHO Model List of Essential Medicines. It blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, reducing peripheral arterial resistance, decreasing aldosterone secretion, and inhibiting the enzymatic degradation of bradykinin, producing potent vasodilation and cardioprotection. Indicated for essential hypertension, heart failure with reduced ejection fraction (HFrEF), post-myocardial infarction, and diabetic nephropathy.

Olmesartan Medoxomil is a potent, orally active prodrug that is rapidly de-esterified during absorption to olmesartan, a selective and insurmountable competitive antagonist at the angiotensin II AT1 receptor. It produces profound, prolonged reductions in systemic vascular resistance and blood pressure throughout the 24-hour dosing interval. Indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents (amlodipine, cilnidipine, chlorthalidone, hydrochlorothiazide).

Amlodipine (or S-Amlodipine, the pure chirally active enantiomer with lower incidence of ankle edema) is a third-generation dihydropyridine calcium channel blocker on the WHO Model List of Essential Medicines. It inhibits transmembrane influx of extracellular calcium ions into vascular smooth muscle and cardiac muscle through L-type channels, resulting in potent peripheral arterial and coronary vasodilation with an exceptionally long half-life (30-50 hours). Indicated for essential hypertension, chronic stable angina pectoris, and vasospastic (Prinzmetal's) angina.

Moxonidine Tablets 0.3 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Amlodipine (or S-Amlodipine, the pure chirally active enantiomer with lower incidence of ankle edema) is a third-generation dihydropyridine calcium channel blocker on the WHO Model List of Essential Medicines. It inhibits transmembrane influx of extracellular calcium ions into vascular smooth muscle and cardiac muscle through L-type channels, resulting in potent peripheral arterial and coronary vasodilation with an exceptionally long half-life (30-50 hours). Indicated for essential hypertension, chronic stable angina pectoris, and vasospastic (Prinzmetal's) angina.

Spironolactone is a synthetic steroid competitive mineralocorticoid receptor (aldosterone) antagonist and potassium-sparing diuretic on the WHO Model List of Essential Medicines. It blocks aldosterone binding in the late distal renal tubules and cortical collecting ducts, increasing sodium and water excretion while conserving potassium and hydrogen ions. In heart failure, it blocks aldosterone-mediated myocardial fibrosis and endothelial dysfunction. Indicated for heart failure with reduced ejection fraction (NYHA class II-IV), primary hyperaldosteronism, cirrhosis with ascites, resistant hypertension, and nephrotic edema.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Streptokinase Injection 15 + 00 + 000 IU is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Warfarin Tablets 5 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Valsartan Tablets 80 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Verapamil Tablets 80 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).

Torsemide Tablets 20 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Etamsylate Tablets 500 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Etamsylate Tablets 250 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).

Acetylsalicylic Acid (Aspirin) Gastro-resistant Tablets 325mg is an evidence-based dermatological formulation. It acts by delivering targeted active therapeutic ingredients to cutaneous lesions to relieve skin pathology, restore barrier integrity, and manage dermatoses.

Adenosine Injection 3mg per ml is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Aspirin (Acetylsalicylic Acid, low-dose 75 mg - 150 mg) is the prototype antiplatelet agent on the WHO Model List of Essential Medicines. It irreversibly acetylates serine 529 of platelet cyclooxygenase-1 (COX-1), permanently suppressing the synthesis of thromboxane A2 (a potent platelet aggregator and vasoconstrictor) for the 7-10 day lifespan of the platelet. Gastro-resistant (enteric-coated) formulations protect the gastric mucosa by dissolving only in the neutral pH of the small intestine. Indicated for secondary prevention of recurrent myocardial infarction, ischemic stroke, transient ischemic attacks (TIAs), and following coronary bypass or stent placement.

Amlodipine and Atenolol is a classic dual-mechanism cardiovascular combination pairing a dihydropyridine calcium channel blocker with a cardioselective beta-1 blocker. Amlodipine lowers peripheral vascular resistance and dilates coronary arteries, while atenolol reduces resting and exercise heart rates, suppresses cardiac contractility, and eliminates the reflex tachycardia typically triggered by dihydropyridine vasodilation. Indicated for essential hypertension and stable chronic angina pectoris.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Statin and Antiplatelet (Aspirin +/- Clopidogrel) cardiovascular polypill formulation. Unites intensive lipid lowering and plaque stabilization (via HMG-CoA reductase inhibition) with antiplatelet thrombus prevention (via irreversible COX-1 inhibition and/or ADP P2Y12 platelet receptor blockade). Indicated for secondary prevention in coronary artery disease, acute coronary syndrome, post-percutaneous coronary intervention (PCI/stenting), and ischemic stroke.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Chlorthalidone Tablets 12.5mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Cilnidipine is a novel fourth-generation calcium channel blocker with unique dual L-type and N-type voltage-gated calcium channel antagonist properties. While L-type blockade dilates vascular smooth muscle, N-type blockade at sympathetic nerve terminals inhibits the pathological release of norepinephrine, suppressing sympathetic nervous hyperactivity, preventing reflex tachycardia, and dilating both afferent and efferent renal arterioles to lower intraglomerular hydrostatic pressure. Indicated for essential hypertension, particularly in patients with morning hypertension, diabetic nephropathy, chronic kidney disease, or ankle edema from amlodipine.

Cilostazol is a quinolinone derivative cellular phosphodiesterase III (PDE-3) inhibitor. It suppresses cyclic AMP degradation, elevating intracellular cAMP in platelets and vascular smooth muscle cells, which inhibits platelet aggregation, blocks vascular smooth muscle proliferation, and produces potent arterial vasodilation. Indicated for the reduction of symptoms of intermittent claudication in peripheral arterial disease (PAD), demonstrated by increased pain-free walking distance.

Spironolactone is a synthetic steroid competitive mineralocorticoid receptor (aldosterone) antagonist and potassium-sparing diuretic on the WHO Model List of Essential Medicines. It blocks aldosterone binding in the late distal renal tubules and cortical collecting ducts, increasing sodium and water excretion while conserving potassium and hydrogen ions. In heart failure, it blocks aldosterone-mediated myocardial fibrosis and endothelial dysfunction. Indicated for heart failure with reduced ejection fraction (NYHA class II-IV), primary hyperaldosteronism, cirrhosis with ascites, resistant hypertension, and nephrotic edema.

Nitroglycerin (Glyceryl Trinitrate) is an organic nitrate vasodilator on the WHO Model List of Essential Medicines. It is denitrated intracellularly to release nitric oxide (NO), stimulating guanylate cyclase, increasing intracellular cyclic GMP, and activating protein kinase G, producing profound relaxation of vascular smooth muscle with preferential dilation of large systemic veins (reducing cardiac preload and myocardial oxygen demand) and epicardial coronary arteries. Indicated for acute relief and prophylaxis of angina pectoris attacks, perioperative hypertension, and acute pulmonary edema.

Hydrochlorothiazide Tablets 12.5mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Isosorbidemononitrate Tablets 20mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Isoxsuprine Hydrochloride Tablets 10mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Olmesartan Medoxomil is a potent, orally active prodrug that is rapidly de-esterified during absorption to olmesartan, a selective and insurmountable competitive antagonist at the angiotensin II AT1 receptor. It produces profound, prolonged reductions in systemic vascular resistance and blood pressure throughout the 24-hour dosing interval. Indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents (amlodipine, cilnidipine, chlorthalidone, hydrochlorothiazide).

Phytomenadione Injection (Vitamin K1) 1mg per 0.5ml is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Erythropoietin Injection 4000 IU is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Erythropoietin Injection 2000 IU is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).

Telmisartan and Metoprolol Succinate (Extended-Release) combines an ARB with a cardioselective beta-1 adrenergic blocker. Telmisartan reduces afterload and inhibits vascular remodeling, while extended-release metoprolol attenuates sympathetic nervous activity, reduces resting and exercise heart rates, lowers myocardial oxygen demand, and stabilizes cardiac rhythm. Indicated for hypertension associated with coronary artery disease, stable angina, post-myocardial infarction, or resting tachycardia.

Telmisartan and Hydrochlorothiazide combines an AT1 angiotensin II receptor antagonist with a thiazide diuretic. Telmisartan suppresses the renin-angiotensin-aldosterone axis, while hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted renal tubules, increasing urinary excretion of sodium, chloride, and water. Telmisartan counteracts diuretic-induced potassium wasting and metabolic disturbances. Indicated for the treatment of hypertension not adequately controlled on telmisartan monotherapy.

Trimetazidine Dihydrochloride is a myocardial metabolic anti-ischemic agent. It selectively inhibits the enzyme 3-ketoacyl-coenzyme A thiolase (3-KAT) in cardiac mitochondria, suppressing fatty acid beta-oxidation and shifting energy metabolism towards glucose oxidation. Glucose oxidation requires less oxygen consumption per unit of ATP produced, preserving myocardial cellular high-energy phosphate (ATP and phosphocreatine) levels during ischemia without altering heart rate, blood pressure, or coronary hemodynamics. Indicated as add-on therapy for the symptomatic treatment of adult patients with stable angina pectoris inadequately controlled by or intolerant to first-line therapies.

Telmisartan and Metoprolol Succinate (Extended-Release) combines an ARB with a cardioselective beta-1 adrenergic blocker. Telmisartan reduces afterload and inhibits vascular remodeling, while extended-release metoprolol attenuates sympathetic nervous activity, reduces resting and exercise heart rates, lowers myocardial oxygen demand, and stabilizes cardiac rhythm. Indicated for hypertension associated with coronary artery disease, stable angina, post-myocardial infarction, or resting tachycardia.

Angiotensin Converting Enzyme (ACE) Inhibitor on the WHO Model List of Essential Medicines. It blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, reducing peripheral arterial resistance, decreasing aldosterone secretion, and inhibiting the enzymatic degradation of bradykinin, producing potent vasodilation and cardioprotection. Indicated for essential hypertension, heart failure with reduced ejection fraction (HFrEF), post-myocardial infarction, and diabetic nephropathy.

Amlodipine (or S-Amlodipine, the pure chirally active enantiomer with lower incidence of ankle edema) is a third-generation dihydropyridine calcium channel blocker on the WHO Model List of Essential Medicines. It inhibits transmembrane influx of extracellular calcium ions into vascular smooth muscle and cardiac muscle through L-type channels, resulting in potent peripheral arterial and coronary vasodilation with an exceptionally long half-life (30-50 hours). Indicated for essential hypertension, chronic stable angina pectoris, and vasospastic (Prinzmetal's) angina.

Protamine Sulphate Injection 10mg per ml is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Selective alpha-1 adrenergic receptor antagonist. It competitively blocks post-junctional alpha-1 receptors on vascular smooth muscle, dilating both arterioles and veins to lower peripheral vascular resistance and systemic blood pressure, while also relaxing smooth muscle in the bladder neck and prostate capsule. Indicated for essential hypertension and benign prostatic hyperplasia (BPH).

Amiloride 2.5mg + Hydrochlorothiazide 25mg Tablet is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Chlorthalidone Tablets 6.25 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Telmisartan and Cilnidipine is an innovative vascular- and renal-protective antihypertensive combination. Telmisartan blocks AT1 angiotensin receptors, while cilnidipine acts as a unique dual L-type and N-type voltage-gated calcium channel blocker. Blockade of sympathetic N-type calcium channels on sympathetic nerve endings inhibits excessive norepinephrine release, preventing reflex tachycardia and dilating both efferent and afferent renal arterioles, which lowers intraglomerular pressure and reduces proteinuria with virtually zero incidence of pedal edema. Indicated for essential hypertension, particularly in patients with metabolic syndrome, diabetes, or renal impairment.

Fenofibrate Tablets 145 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Olmesartan Medoxomil is a potent, orally active prodrug that is rapidly de-esterified during absorption to olmesartan, a selective and insurmountable competitive antagonist at the angiotensin II AT1 receptor. It produces profound, prolonged reductions in systemic vascular resistance and blood pressure throughout the 24-hour dosing interval. Indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents (amlodipine, cilnidipine, chlorthalidone, hydrochlorothiazide).

Olmesartan Medoxomil is a potent, orally active prodrug that is rapidly de-esterified during absorption to olmesartan, a selective and insurmountable competitive antagonist at the angiotensin II AT1 receptor. It produces profound, prolonged reductions in systemic vascular resistance and blood pressure throughout the 24-hour dosing interval. Indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents (amlodipine, cilnidipine, chlorthalidone, hydrochlorothiazide).

Prasugrel Hydrochloride is a third-generation oral thienopyridine prodrug that irreversibly blocks the platelet P2Y12 ADP receptor. It undergoes single-step CYP450 bioactivation (primarily CYP3A4 and CYP2B6), achieving more rapid, potent, and consistent platelet inhibition than clopidogrel with minimal resistance. Indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI).

Statin and Antiplatelet (Aspirin +/- Clopidogrel) cardiovascular polypill formulation. Unites intensive lipid lowering and plaque stabilization (via HMG-CoA reductase inhibition) with antiplatelet thrombus prevention (via irreversible COX-1 inhibition and/or ADP P2Y12 platelet receptor blockade). Indicated for secondary prevention in coronary artery disease, acute coronary syndrome, post-percutaneous coronary intervention (PCI/stenting), and ischemic stroke.

Statin and Antiplatelet (Aspirin +/- Clopidogrel) cardiovascular polypill formulation. Unites intensive lipid lowering and plaque stabilization (via HMG-CoA reductase inhibition) with antiplatelet thrombus prevention (via irreversible COX-1 inhibition and/or ADP P2Y12 platelet receptor blockade). Indicated for secondary prevention in coronary artery disease, acute coronary syndrome, post-percutaneous coronary intervention (PCI/stenting), and ischemic stroke.

Telmisartan, Amlodipine, and Hydrochlorothiazide is a triple-action fixed-dose antihypertensive combination uniting three complementary hemodynamic mechanisms: an angiotensin II receptor blocker (ARB), a dihydropyridine calcium channel blocker (CCB), and a thiazide diuretic. Telmisartan blocks AT1 receptors and activates PPAR-gamma; amlodipine relaxes peripheral arterial smooth muscle; and hydrochlorothiazide promotes natriuresis, eliminating excess intravascular volume. Indicated for moderate-to-severe essential hypertension in patients not adequately controlled on dual-therapy regimens.

Telmisartan and Chlorthalidone is a potent, long-acting dual antihypertensive combination. Telmisartan delivers selective 24-hour AT1 receptor blockade, while chlorthalidone, a long-acting monosulfonamyl thiazide-like diuretic with a terminal elimination half-life of 40-60 hours, provides sustained intravascular volume and vascular resistance reduction throughout day and night. Indicated for stage 2 hypertension and nocturnal/early morning hypertension surges.

Terlipressin Injection 1000 mcg (1 mg/10ml) is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Amiodarone Hydrochloride is a broad-spectrum Class III antiarrhythmic agent on the WHO Model List of Essential Medicines. It predominantly blocks voltage-gated potassium channels, prolonging myocardial action potential duration and effective refractory period across all cardiac tissues, while also exhibiting Class I (sodium channel block), Class II (antiadrenergic non-competitive beta-block), and Class IV (calcium channel block) actions. Features an enormous volume of distribution and an elimination half-life of 40 to 60 days. Indicated for life-threatening ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation) and supraventricular arrhythmias (atrial fibrillation/flutter).

Amlodipine (or S-Amlodipine, the pure chirally active enantiomer with lower incidence of ankle edema) is a third-generation dihydropyridine calcium channel blocker on the WHO Model List of Essential Medicines. It inhibits transmembrane influx of extracellular calcium ions into vascular smooth muscle and cardiac muscle through L-type channels, resulting in potent peripheral arterial and coronary vasodilation with an exceptionally long half-life (30-50 hours). Indicated for essential hypertension, chronic stable angina pectoris, and vasospastic (Prinzmetal's) angina.

Statin and Antiplatelet (Aspirin +/- Clopidogrel) cardiovascular polypill formulation. Unites intensive lipid lowering and plaque stabilization (via HMG-CoA reductase inhibition) with antiplatelet thrombus prevention (via irreversible COX-1 inhibition and/or ADP P2Y12 platelet receptor blockade). Indicated for secondary prevention in coronary artery disease, acute coronary syndrome, post-percutaneous coronary intervention (PCI/stenting), and ischemic stroke.

Statin and Antiplatelet (Aspirin +/- Clopidogrel) cardiovascular polypill formulation. Unites intensive lipid lowering and plaque stabilization (via HMG-CoA reductase inhibition) with antiplatelet thrombus prevention (via irreversible COX-1 inhibition and/or ADP P2Y12 platelet receptor blockade). Indicated for secondary prevention in coronary artery disease, acute coronary syndrome, post-percutaneous coronary intervention (PCI/stenting), and ischemic stroke.

Statin and Antiplatelet (Aspirin +/- Clopidogrel) cardiovascular polypill formulation. Unites intensive lipid lowering and plaque stabilization (via HMG-CoA reductase inhibition) with antiplatelet thrombus prevention (via irreversible COX-1 inhibition and/or ADP P2Y12 platelet receptor blockade). Indicated for secondary prevention in coronary artery disease, acute coronary syndrome, post-percutaneous coronary intervention (PCI/stenting), and ischemic stroke.

Azilsartan 40mg + Chlorthalidone 6.25mg Tablet is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Azilsartan Medoxomil 40mg + Chlorthalidone 12.5mg Tablets is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Azilsartan Medoxomil Tablets 40mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Cilnidipine is a novel fourth-generation calcium channel blocker with unique dual L-type and N-type voltage-gated calcium channel antagonist properties. While L-type blockade dilates vascular smooth muscle, N-type blockade at sympathetic nerve terminals inhibits the pathological release of norepinephrine, suppressing sympathetic nervous hyperactivity, preventing reflex tachycardia, and dilating both afferent and efferent renal arterioles to lower intraglomerular hydrostatic pressure. Indicated for essential hypertension, particularly in patients with morning hypertension, diabetic nephropathy, chronic kidney disease, or ankle edema from amlodipine.

Cilnidipine is a novel fourth-generation calcium channel blocker with unique dual L-type and N-type voltage-gated calcium channel antagonist properties. While L-type blockade dilates vascular smooth muscle, N-type blockade at sympathetic nerve terminals inhibits the pathological release of norepinephrine, suppressing sympathetic nervous hyperactivity, preventing reflex tachycardia, and dilating both afferent and efferent renal arterioles to lower intraglomerular hydrostatic pressure. Indicated for essential hypertension, particularly in patients with morning hypertension, diabetic nephropathy, chronic kidney disease, or ankle edema from amlodipine.

Clopidogrel and Aspirin is the cornerstone Dual Antiplatelet Therapy (DAPT) on the WHO Model List of Essential Medicines. Aspirin irreversibly acetylates platelet cyclooxygenase-1 (COX-1), blocking thromboxane A2 production, while clopidogrel is an oral thienopyridine prodrug whose active metabolite irreversibly binds to platelet P2Y12 adenosine diphosphate (ADP) receptors, preventing ADP-mediated glycoprotein IIb/IIIa activation. This dual blockade potently inhibits platelet aggregation across complementary pathways. Indicated for acute coronary syndromes (STEMI, NSTEMI, unstable angina) and prevention of subacute stent thrombosis following percutaneous coronary intervention (PCI).

Dabigatran Etexilate is an oral prodrug of dabigatran, a potent, competitive, reversible direct thrombin (Factor IIa) inhibitor on the WHO Model List of Essential Medicines. It binds to the active site of both free and clot-bound thrombin, preventing thrombin-mediated conversion of fibrinogen into fibrin and blocking thrombin-induced platelet aggregation. Specific reversal agent (idarucizumab) is available. Indicated for stroke prevention in non-valvular atrial fibrillation and treatment/prophylaxis of DVT and pulmonary embolism.

Dabigatran Etexilate is an oral prodrug of dabigatran, a potent, competitive, reversible direct thrombin (Factor IIa) inhibitor on the WHO Model List of Essential Medicines. It binds to the active site of both free and clot-bound thrombin, preventing thrombin-mediated conversion of fibrinogen into fibrin and blocking thrombin-induced platelet aggregation. Specific reversal agent (idarucizumab) is available. Indicated for stroke prevention in non-valvular atrial fibrillation and treatment/prophylaxis of DVT and pulmonary embolism.

Diltiazem Hydrochloride Extended Release Capsules 120 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Eplerenone Tablets 25 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Isosorbide 20mg + Hydralazine 37.5mg Tablets is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Ivabradine Hydrochloride is a hyperpolarization-activated cyclic nucleotide-gated (HCN) channel blocker on the WHO Model List of Essential Medicines. It selectively and specifically inhibits the cardiac pacemaker If ("funny") current in the sinoatrial node, slowing diastolic depolarization and reducing resting and exercise heart rates in a dose-dependent manner without affecting ventricular repolarization, myocardial contractility, intracardiac conduction, or blood pressure. Indicated for chronic heart failure with reduced ejection fraction (HFrEF, NYHA II-IV, LVEF <= 35%, sinus rhythm, HR >= 70 bpm) and symptomatic management of chronic stable angina.

Angiotensin Converting Enzyme (ACE) Inhibitor on the WHO Model List of Essential Medicines. It blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, reducing peripheral arterial resistance, decreasing aldosterone secretion, and inhibiting the enzymatic degradation of bradykinin, producing potent vasodilation and cardioprotection. Indicated for essential hypertension, heart failure with reduced ejection fraction (HFrEF), post-myocardial infarction, and diabetic nephropathy.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Amlodipine (or S-Amlodipine, the pure chirally active enantiomer with lower incidence of ankle edema) is a third-generation dihydropyridine calcium channel blocker on the WHO Model List of Essential Medicines. It inhibits transmembrane influx of extracellular calcium ions into vascular smooth muscle and cardiac muscle through L-type channels, resulting in potent peripheral arterial and coronary vasodilation with an exceptionally long half-life (30-50 hours). Indicated for essential hypertension, chronic stable angina pectoris, and vasospastic (Prinzmetal's) angina.

Nicorandil is a dual-action antianginal agent possessing both ATP-sensitive potassium channel (K_ATP) opening and nitrate-like vasodilating properties. By opening sarcolemmal K_ATP channels, it hyperpolarizes vascular smooth muscle membranes, dilating coronary arterioles and reducing cardiac afterload, while its nitrate moiety stimulates guanylate cyclase to dilate systemic veins and reduce preload. Also provides cardioprotective ischemic preconditioning. Indicated for the prevention and long-term treatment of chronic stable angina pectoris.

Nicorandil is a dual-action antianginal agent possessing both ATP-sensitive potassium channel (K_ATP) opening and nitrate-like vasodilating properties. By opening sarcolemmal K_ATP channels, it hyperpolarizes vascular smooth muscle membranes, dilating coronary arterioles and reducing cardiac afterload, while its nitrate moiety stimulates guanylate cyclase to dilate systemic veins and reduce preload. Also provides cardioprotective ischemic preconditioning. Indicated for the prevention and long-term treatment of chronic stable angina pectoris.

Nicoumalone/Acenocoumarol Tablets 1 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Nicoumalone/Acenocoumarol Tablets 3 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Nicoumalone/Acenocoumarol Tablets 4 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Nifedipine Sustained Release Tablets 10mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Olmesartan Medoxomil is a potent, orally active prodrug that is rapidly de-esterified during absorption to olmesartan, a selective and insurmountable competitive antagonist at the angiotensin II AT1 receptor. It produces profound, prolonged reductions in systemic vascular resistance and blood pressure throughout the 24-hour dosing interval. Indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents (amlodipine, cilnidipine, chlorthalidone, hydrochlorothiazide).

Olmesartan Medoxomil is a potent, orally active prodrug that is rapidly de-esterified during absorption to olmesartan, a selective and insurmountable competitive antagonist at the angiotensin II AT1 receptor. It produces profound, prolonged reductions in systemic vascular resistance and blood pressure throughout the 24-hour dosing interval. Indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents (amlodipine, cilnidipine, chlorthalidone, hydrochlorothiazide).

Olmesartan Medoxomil is a potent, orally active prodrug that is rapidly de-esterified during absorption to olmesartan, a selective and insurmountable competitive antagonist at the angiotensin II AT1 receptor. It produces profound, prolonged reductions in systemic vascular resistance and blood pressure throughout the 24-hour dosing interval. Indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents (amlodipine, cilnidipine, chlorthalidone, hydrochlorothiazide).

Selective alpha-1 adrenergic receptor antagonist. It competitively blocks post-junctional alpha-1 receptors on vascular smooth muscle, dilating both arterioles and veins to lower peripheral vascular resistance and systemic blood pressure, while also relaxing smooth muscle in the bladder neck and prostate capsule. Indicated for essential hypertension and benign prostatic hyperplasia (BPH).

Angiotensin Converting Enzyme (ACE) Inhibitor on the WHO Model List of Essential Medicines. It blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, reducing peripheral arterial resistance, decreasing aldosterone secretion, and inhibiting the enzymatic degradation of bradykinin, producing potent vasodilation and cardioprotection. Indicated for essential hypertension, heart failure with reduced ejection fraction (HFrEF), post-myocardial infarction, and diabetic nephropathy.

Ranolazine is a piperazine derivative late sodium current (I_Na,late) inhibitor. In ischemic cardiomyocytes, pathological enhancement of late sodium influx leads to intracellular sodium accumulation, triggering the reverse mode of the Na+/Ca2+ exchanger and causing toxic intracellular calcium overload, diastolic left ventricular wall tension, and microvascular compression. Ranolazine selectively inhibits I_Na,late, attenuating calcium overload and improving diastolic myocardial perfusion without lowering heart rate or blood pressure. Indicated for the treatment of chronic stable angina pectoris.

Rivaroxaban is an oral, direct, and selective competitive factor Xa inhibitor (DOAC) on the WHO Model List of Essential Medicines. By blocking factor Xa, it interrupts both intrinsic and extrinsic coagulation cascades, preventing thrombin generation and clot propagation. Indicated for stroke prevention in non-valvular atrial fibrillation, treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), and CAD/PAD risk reduction (in combination with aspirin).

Rivaroxaban is an oral, direct, and selective competitive factor Xa inhibitor (DOAC) on the WHO Model List of Essential Medicines. By blocking factor Xa, it interrupts both intrinsic and extrinsic coagulation cascades, preventing thrombin generation and clot propagation. Indicated for stroke prevention in non-valvular atrial fibrillation, treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), and CAD/PAD risk reduction (in combination with aspirin).

Statin and Fenofibrate is a comprehensive dual-action lipid-regulating combination. The statin (Atorvastatin or Rosuvastatin) competitively inhibits HMG-CoA reductase, potently lowering LDL cholesterol and apolipoprotein B, while fenofibrate, a fibric acid derivative, activates peroxisome proliferator-activated receptor-alpha (PPAR-alpha), dramatically reducing triglycerides (by 30-50%), increasing HDL cholesterol, and converting atherogenic small dense LDL into larger buoyant particles. Indicated for mixed dyslipidemia, severe hypertriglyceridemia, and diabetic dyslipidemia.

HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).

Statin and Antiplatelet (Aspirin +/- Clopidogrel) cardiovascular polypill formulation. Unites intensive lipid lowering and plaque stabilization (via HMG-CoA reductase inhibition) with antiplatelet thrombus prevention (via irreversible COX-1 inhibition and/or ADP P2Y12 platelet receptor blockade). Indicated for secondary prevention in coronary artery disease, acute coronary syndrome, post-percutaneous coronary intervention (PCI/stenting), and ischemic stroke.

Statin and Antiplatelet (Aspirin +/- Clopidogrel) cardiovascular polypill formulation. Unites intensive lipid lowering and plaque stabilization (via HMG-CoA reductase inhibition) with antiplatelet thrombus prevention (via irreversible COX-1 inhibition and/or ADP P2Y12 platelet receptor blockade). Indicated for secondary prevention in coronary artery disease, acute coronary syndrome, post-percutaneous coronary intervention (PCI/stenting), and ischemic stroke.

Amlodipine (or S-Amlodipine, the pure chirally active enantiomer with lower incidence of ankle edema) is a third-generation dihydropyridine calcium channel blocker on the WHO Model List of Essential Medicines. It inhibits transmembrane influx of extracellular calcium ions into vascular smooth muscle and cardiac muscle through L-type channels, resulting in potent peripheral arterial and coronary vasodilation with an exceptionally long half-life (30-50 hours). Indicated for essential hypertension, chronic stable angina pectoris, and vasospastic (Prinzmetal's) angina.

Amlodipine and Atenolol is a classic dual-mechanism cardiovascular combination pairing a dihydropyridine calcium channel blocker with a cardioselective beta-1 blocker. Amlodipine lowers peripheral vascular resistance and dilates coronary arteries, while atenolol reduces resting and exercise heart rates, suppresses cardiac contractility, and eliminates the reflex tachycardia typically triggered by dihydropyridine vasodilation. Indicated for essential hypertension and stable chronic angina pectoris.

Sacubitril and Valsartan is a first-in-class Angiotensin Receptor-Neprilysin Inhibitor (ARNI) on the WHO Model List of Essential Medicines. Sacubitril is a prodrug whose active metabolite LBQ657 inhibits neprilysin (neutral endopeptidase), preventing the breakdown of endogenous natriuretic peptides (ANP, BNP, CNP) and promoting vasodilation, natriuresis, diuresis, and anti-remodeling, while valsartan selectively blocks the AT1 receptor, countering neprilysin-induced angiotensin II accumulation. Indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure (NYHA II-IV and reduced ejection fraction).

Sacubitril and Valsartan is a first-in-class Angiotensin Receptor-Neprilysin Inhibitor (ARNI) on the WHO Model List of Essential Medicines. Sacubitril is a prodrug whose active metabolite LBQ657 inhibits neprilysin (neutral endopeptidase), preventing the breakdown of endogenous natriuretic peptides (ANP, BNP, CNP) and promoting vasodilation, natriuresis, diuresis, and anti-remodeling, while valsartan selectively blocks the AT1 receptor, countering neprilysin-induced angiotensin II accumulation. Indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure (NYHA II-IV and reduced ejection fraction).

Saroglitazar Tablets 4mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Telmisartan and Amlodipine is a synergistic dual antihypertensive formulation. Telmisartan blocks vasoconstrictor and aldosterone-secreting effects of angiotensin II at AT1 receptors and improves insulin sensitivity via partial PPAR-gamma agonism, while amlodipine selectively inhibits transmembrane calcium influx in vascular smooth muscle, producing peripheral arteriolar vasodilation. Telmisartan post-capillary venodilation mitigates amlodipine-induced pre-capillary peripheral ankle edema. Indicated for essential hypertension in patients whose blood pressure is not adequately controlled on monotherapy.

Telmisartan and Cilnidipine is an innovative vascular- and renal-protective antihypertensive combination. Telmisartan blocks AT1 angiotensin receptors, while cilnidipine acts as a unique dual L-type and N-type voltage-gated calcium channel blocker. Blockade of sympathetic N-type calcium channels on sympathetic nerve endings inhibits excessive norepinephrine release, preventing reflex tachycardia and dilating both efferent and afferent renal arterioles, which lowers intraglomerular pressure and reduces proteinuria with virtually zero incidence of pedal edema. Indicated for essential hypertension, particularly in patients with metabolic syndrome, diabetes, or renal impairment.

Telmisartan is a potent, non-peptide, long-acting angiotensin II type 1 (AT1) receptor antagonist on the WHO Model List of Essential Medicines. It exhibits an exceptionally long elimination half-life (around 24 hours) providing sustained 24-hour blood pressure control with high trough-to-peak ratio, and uniquely functions as a partial agonist at peroxisome proliferator-activated receptor-gamma (PPAR-gamma), improving glucose handling and lipid metabolism. Indicated for essential hypertension and cardiovascular risk reduction in patients with coronary artery disease, stroke, or diabetes with end-organ damage.

Telmisartan and Amlodipine is a synergistic dual antihypertensive formulation. Telmisartan blocks vasoconstrictor and aldosterone-secreting effects of angiotensin II at AT1 receptors and improves insulin sensitivity via partial PPAR-gamma agonism, while amlodipine selectively inhibits transmembrane calcium influx in vascular smooth muscle, producing peripheral arteriolar vasodilation. Telmisartan post-capillary venodilation mitigates amlodipine-induced pre-capillary peripheral ankle edema. Indicated for essential hypertension in patients whose blood pressure is not adequately controlled on monotherapy.

Telmisartan and Amlodipine is a synergistic dual antihypertensive formulation. Telmisartan blocks vasoconstrictor and aldosterone-secreting effects of angiotensin II at AT1 receptors and improves insulin sensitivity via partial PPAR-gamma agonism, while amlodipine selectively inhibits transmembrane calcium influx in vascular smooth muscle, producing peripheral arteriolar vasodilation. Telmisartan post-capillary venodilation mitigates amlodipine-induced pre-capillary peripheral ankle edema. Indicated for essential hypertension in patients whose blood pressure is not adequately controlled on monotherapy.

Telmisartan and Chlorthalidone is a potent, long-acting dual antihypertensive combination. Telmisartan delivers selective 24-hour AT1 receptor blockade, while chlorthalidone, a long-acting monosulfonamyl thiazide-like diuretic with a terminal elimination half-life of 40-60 hours, provides sustained intravascular volume and vascular resistance reduction throughout day and night. Indicated for stage 2 hypertension and nocturnal/early morning hypertension surges.

Ticagrelor is a direct-acting, reversibly-binding cyclopentyltriazolopyrimidine P2Y12 platelet antagonist on the WHO Model List of Essential Medicines. Unlike thienopyridines (clopidogrel, prasugrel), it does not require metabolic bioactivation, offering rapid, predictable, and reversible platelet inhibition. Indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS) or a history of myocardial infarction and high risk of developing an atherothrombotic event.

Tolvaptan Tablets 15mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Spironolactone is a synthetic steroid competitive mineralocorticoid receptor (aldosterone) antagonist and potassium-sparing diuretic on the WHO Model List of Essential Medicines. It blocks aldosterone binding in the late distal renal tubules and cortical collecting ducts, increasing sodium and water excretion while conserving potassium and hydrogen ions. In heart failure, it blocks aldosterone-mediated myocardial fibrosis and endothelial dysfunction. Indicated for heart failure with reduced ejection fraction (NYHA class II-IV), primary hyperaldosteronism, cirrhosis with ascites, resistant hypertension, and nephrotic edema.

Trimetazidine Dihydrochloride is a myocardial metabolic anti-ischemic agent. It selectively inhibits the enzyme 3-ketoacyl-coenzyme A thiolase (3-KAT) in cardiac mitochondria, suppressing fatty acid beta-oxidation and shifting energy metabolism towards glucose oxidation. Glucose oxidation requires less oxygen consumption per unit of ATP produced, preserving myocardial cellular high-energy phosphate (ATP and phosphocreatine) levels during ischemia without altering heart rate, blood pressure, or coronary hemodynamics. Indicated as add-on therapy for the symptomatic treatment of adult patients with stable angina pectoris inadequately controlled by or intolerant to first-line therapies.

Ranolazine is a piperazine derivative late sodium current (I_Na,late) inhibitor. In ischemic cardiomyocytes, pathological enhancement of late sodium influx leads to intracellular sodium accumulation, triggering the reverse mode of the Na+/Ca2+ exchanger and causing toxic intracellular calcium overload, diastolic left ventricular wall tension, and microvascular compression. Ranolazine selectively inhibits I_Na,late, attenuating calcium overload and improving diastolic myocardial perfusion without lowering heart rate or blood pressure. Indicated for the treatment of chronic stable angina pectoris.

Telmisartan is a potent, non-peptide, long-acting angiotensin II type 1 (AT1) receptor antagonist on the WHO Model List of Essential Medicines. It exhibits an exceptionally long elimination half-life (around 24 hours) providing sustained 24-hour blood pressure control with high trough-to-peak ratio, and uniquely functions as a partial agonist at peroxisome proliferator-activated receptor-gamma (PPAR-gamma), improving glucose handling and lipid metabolism. Indicated for essential hypertension and cardiovascular risk reduction in patients with coronary artery disease, stroke, or diabetes with end-organ damage.

Minoxidil oral tablets (5 mg, 10 mg) is a potent direct-acting peripheral arteriolar vasodilator. It acts by opening ATP-sensitive potassium channels in vascular smooth muscle, causing smooth muscle relaxation, profound vasodilation, and reflex sympathetic stimulation. Indicated for severe, refractory hypertension that has failed to respond to multidrug regimens (administered with a beta-blocker and loop diuretic), and used off-label in low doses for refractory androgenetic alopecia under strict specialist oversight.

Amlodipine (or S-Amlodipine, the pure chirally active enantiomer with lower incidence of ankle edema) is a third-generation dihydropyridine calcium channel blocker on the WHO Model List of Essential Medicines. It inhibits transmembrane influx of extracellular calcium ions into vascular smooth muscle and cardiac muscle through L-type channels, resulting in potent peripheral arterial and coronary vasodilation with an exceptionally long half-life (30-50 hours). Indicated for essential hypertension, chronic stable angina pectoris, and vasospastic (Prinzmetal's) angina.

HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).

Telmisartan and Statin (Rosuvastatin or Atorvastatin) is a dual cardio-metabolic polypill formulation uniting an ARB with an HMG-CoA reductase inhibitor. Telmisartan controls systemic blood pressure and improves vascular endothelial function, while the statin potently reduces hepatic cholesterol synthesis, lowering LDL-C and apolipoprotein B while stabilizing atherosclerotic plaques. Indicated for co-existing essential hypertension and hyperlipidemia/dyslipidemia to mitigate cardiovascular morbidity and stroke.

Statin and Antiplatelet (Aspirin +/- Clopidogrel) cardiovascular polypill formulation. Unites intensive lipid lowering and plaque stabilization (via HMG-CoA reductase inhibition) with antiplatelet thrombus prevention (via irreversible COX-1 inhibition and/or ADP P2Y12 platelet receptor blockade). Indicated for secondary prevention in coronary artery disease, acute coronary syndrome, post-percutaneous coronary intervention (PCI/stenting), and ischemic stroke.

Statin and Antiplatelet (Aspirin +/- Clopidogrel) cardiovascular polypill formulation. Unites intensive lipid lowering and plaque stabilization (via HMG-CoA reductase inhibition) with antiplatelet thrombus prevention (via irreversible COX-1 inhibition and/or ADP P2Y12 platelet receptor blockade). Indicated for secondary prevention in coronary artery disease, acute coronary syndrome, post-percutaneous coronary intervention (PCI/stenting), and ischemic stroke.

Statin and Antiplatelet (Aspirin +/- Clopidogrel) cardiovascular polypill formulation. Unites intensive lipid lowering and plaque stabilization (via HMG-CoA reductase inhibition) with antiplatelet thrombus prevention (via irreversible COX-1 inhibition and/or ADP P2Y12 platelet receptor blockade). Indicated for secondary prevention in coronary artery disease, acute coronary syndrome, post-percutaneous coronary intervention (PCI/stenting), and ischemic stroke.

HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Cilnidipine is a novel fourth-generation calcium channel blocker with unique dual L-type and N-type voltage-gated calcium channel antagonist properties. While L-type blockade dilates vascular smooth muscle, N-type blockade at sympathetic nerve terminals inhibits the pathological release of norepinephrine, suppressing sympathetic nervous hyperactivity, preventing reflex tachycardia, and dilating both afferent and efferent renal arterioles to lower intraglomerular hydrostatic pressure. Indicated for essential hypertension, particularly in patients with morning hypertension, diabetic nephropathy, chronic kidney disease, or ankle edema from amlodipine.

Cilnidipine is a novel fourth-generation calcium channel blocker with unique dual L-type and N-type voltage-gated calcium channel antagonist properties. While L-type blockade dilates vascular smooth muscle, N-type blockade at sympathetic nerve terminals inhibits the pathological release of norepinephrine, suppressing sympathetic nervous hyperactivity, preventing reflex tachycardia, and dilating both afferent and efferent renal arterioles to lower intraglomerular hydrostatic pressure. Indicated for essential hypertension, particularly in patients with morning hypertension, diabetic nephropathy, chronic kidney disease, or ankle edema from amlodipine.

Cilnidipine is a novel fourth-generation calcium channel blocker with unique dual L-type and N-type voltage-gated calcium channel antagonist properties. While L-type blockade dilates vascular smooth muscle, N-type blockade at sympathetic nerve terminals inhibits the pathological release of norepinephrine, suppressing sympathetic nervous hyperactivity, preventing reflex tachycardia, and dilating both afferent and efferent renal arterioles to lower intraglomerular hydrostatic pressure. Indicated for essential hypertension, particularly in patients with morning hypertension, diabetic nephropathy, chronic kidney disease, or ankle edema from amlodipine.

Cod liver oil 300MG + Evening primrose oil 300MG + Omega-3 fatty acid 90MG + Vitamin E 10MG Soft Gelatin Capsules is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Dabigatran Etexilate is an oral prodrug of dabigatran, a potent, competitive, reversible direct thrombin (Factor IIa) inhibitor on the WHO Model List of Essential Medicines. It binds to the active site of both free and clot-bound thrombin, preventing thrombin-mediated conversion of fibrinogen into fibrin and blocking thrombin-induced platelet aggregation. Specific reversal agent (idarucizumab) is available. Indicated for stroke prevention in non-valvular atrial fibrillation and treatment/prophylaxis of DVT and pulmonary embolism.

Spironolactone is a synthetic steroid competitive mineralocorticoid receptor (aldosterone) antagonist and potassium-sparing diuretic on the WHO Model List of Essential Medicines. It blocks aldosterone binding in the late distal renal tubules and cortical collecting ducts, increasing sodium and water excretion while conserving potassium and hydrogen ions. In heart failure, it blocks aldosterone-mediated myocardial fibrosis and endothelial dysfunction. Indicated for heart failure with reduced ejection fraction (NYHA class II-IV), primary hyperaldosteronism, cirrhosis with ascites, resistant hypertension, and nephrotic edema.

Isosorbide Mononitrate Sustained release Tablets 50mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Telmisartan and Chlorthalidone is a potent, long-acting dual antihypertensive combination. Telmisartan delivers selective 24-hour AT1 receptor blockade, while chlorthalidone, a long-acting monosulfonamyl thiazide-like diuretic with a terminal elimination half-life of 40-60 hours, provides sustained intravascular volume and vascular resistance reduction throughout day and night. Indicated for stage 2 hypertension and nocturnal/early morning hypertension surges.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Nitroglycerin (Glyceryl Trinitrate) is an organic nitrate vasodilator on the WHO Model List of Essential Medicines. It is denitrated intracellularly to release nitric oxide (NO), stimulating guanylate cyclase, increasing intracellular cyclic GMP, and activating protein kinase G, producing profound relaxation of vascular smooth muscle with preferential dilation of large systemic veins (reducing cardiac preload and myocardial oxygen demand) and epicardial coronary arteries. Indicated for acute relief and prophylaxis of angina pectoris attacks, perioperative hypertension, and acute pulmonary edema.

Torasemide and Spironolactone is a balanced dual-action diuretic formulation. Torasemide is a high-potency pyridine-sulfonylurea loop diuretic that inhibits the Na+/K+/2Cl- cotransporter in the thick ascending limb of the loop of Henle, while spironolactone is a competitive aldosterone receptor antagonist in the distal convoluted tubule and collecting duct. Spironolactone prevents loop diuretic-induced potassium wasting and secondary hyperaldosteronism, reducing cardiac fibrosis while promoting sustained natriuresis. Indicated for resistant edema associated with congestive heart failure, hepatic cirrhosis with ascites, and nephrotic syndrome.

Telmisartan and Chlorthalidone is a potent, long-acting dual antihypertensive combination. Telmisartan delivers selective 24-hour AT1 receptor blockade, while chlorthalidone, a long-acting monosulfonamyl thiazide-like diuretic with a terminal elimination half-life of 40-60 hours, provides sustained intravascular volume and vascular resistance reduction throughout day and night. Indicated for stage 2 hypertension and nocturnal/early morning hypertension surges.

Torsemide Tablets 100mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Valsartan Tablets 40 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Verapamil Tablets 40mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Warfarin Tablets 1mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Warfarin Tablets 2mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Combikit of Eplerenone Tablets 25mg + Torsemide Tablets 10mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).

Advanced next-generation dihydropyridine calcium channel blocker (L/T-type or L/N/T-type blocker). Provides gradual, prolonged systemic vasodilation with high vascular selectivity and minimal reflex sympathetic stimulation, protecting coronary, cerebral, and renal microvasculature. Indicated for essential hypertension, renal parenchymal hypertension, and angina pectoris.

Angiotensin Converting Enzyme (ACE) Inhibitor on the WHO Model List of Essential Medicines. It blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, reducing peripheral arterial resistance, decreasing aldosterone secretion, and inhibiting the enzymatic degradation of bradykinin, producing potent vasodilation and cardioprotection. Indicated for essential hypertension, heart failure with reduced ejection fraction (HFrEF), post-myocardial infarction, and diabetic nephropathy.

Fenofibrate Capsules 200mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Metolazone is a quinazoline-derivative thiazide-like diuretic. It inhibits sodium reabsorption at the cortical diluting segment of the distal renal tubule and proximal tubule. Uniquely, it retains its diuretic potency even in advanced renal failure (GFR < 20 mL/min) where standard thiazides fail, and exhibits profound synergistic diuresis ("sequential nephron blockade") when combined with loop diuretics. Indicated for severe refractory edema accompanying congestive heart failure and renal disease, and hypertension.

Moxonidine Tablets 0.2mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Angiotensin Converting Enzyme (ACE) Inhibitor on the WHO Model List of Essential Medicines. It blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, reducing peripheral arterial resistance, decreasing aldosterone secretion, and inhibiting the enzymatic degradation of bradykinin, producing potent vasodilation and cardioprotection. Indicated for essential hypertension, heart failure with reduced ejection fraction (HFrEF), post-myocardial infarction, and diabetic nephropathy.

Ropinirole Tablets 0.5mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Telmisartan, Amlodipine, and Hydrochlorothiazide is a triple-action fixed-dose antihypertensive combination uniting three complementary hemodynamic mechanisms: an angiotensin II receptor blocker (ARB), a dihydropyridine calcium channel blocker (CCB), and a thiazide diuretic. Telmisartan blocks AT1 receptors and activates PPAR-gamma; amlodipine relaxes peripheral arterial smooth muscle; and hydrochlorothiazide promotes natriuresis, eliminating excess intravascular volume. Indicated for moderate-to-severe essential hypertension in patients not adequately controlled on dual-therapy regimens.

Verapamil Hydrochloride Prolonged Release 120mg Tablets is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Angiotensin Converting Enzyme (ACE) Inhibitor on the WHO Model List of Essential Medicines. It blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, reducing peripheral arterial resistance, decreasing aldosterone secretion, and inhibiting the enzymatic degradation of bradykinin, producing potent vasodilation and cardioprotection. Indicated for essential hypertension, heart failure with reduced ejection fraction (HFrEF), post-myocardial infarction, and diabetic nephropathy.

Angiotensin Converting Enzyme (ACE) Inhibitor on the WHO Model List of Essential Medicines. It blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, reducing peripheral arterial resistance, decreasing aldosterone secretion, and inhibiting the enzymatic degradation of bradykinin, producing potent vasodilation and cardioprotection. Indicated for essential hypertension, heart failure with reduced ejection fraction (HFrEF), post-myocardial infarction, and diabetic nephropathy.

Micronized Purified Flavonoid Fraction (MPFF; Diosmin 90% and Hesperidin 10%) is an oral phlebotropic and vascular-protective agent. Micronization reduces particle size (< 2 micrometers), drastically enhancing intestinal absorption. It increases venous tone by prolonging noradrenergic activity on venous walls, enhances lymphatic drainage, protects microvascular capillaries against hyperpermeability, and inhibits leukocyte adhesion and activation, mitigating chronic venous inflammation. Indicated for chronic venous insufficiency (CVI; varicose veins, venous ulcers, heaviness, leg swelling) and acute hemorrhoidal attacks.

Sacubitril and Valsartan is a first-in-class Angiotensin Receptor-Neprilysin Inhibitor (ARNI) on the WHO Model List of Essential Medicines. Sacubitril is a prodrug whose active metabolite LBQ657 inhibits neprilysin (neutral endopeptidase), preventing the breakdown of endogenous natriuretic peptides (ANP, BNP, CNP) and promoting vasodilation, natriuresis, diuresis, and anti-remodeling, while valsartan selectively blocks the AT1 receptor, countering neprilysin-induced angiotensin II accumulation. Indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure (NYHA II-IV and reduced ejection fraction).

Losartan Potassium and Hydrochlorothiazide combines a selective AT1 receptor blocker with a thiazide diuretic on the WHO Model List of Essential Medicines. Losartan blocks angiotensin II-induced vasoconstriction and uniquely possesses intrinsic uricosuric properties that increase uric acid excretion, offsetting the hyperuricemic tendency of hydrochlorothiazide, while hydrochlorothiazide reduces extracellular fluid volume. Indicated for the treatment of hypertension not adequately controlled on monotherapy and for reducing stroke risk in hypertensive patients with left ventricular hypertrophy.

Amlodipine (or S-Amlodipine, the pure chirally active enantiomer with lower incidence of ankle edema) is a third-generation dihydropyridine calcium channel blocker on the WHO Model List of Essential Medicines. It inhibits transmembrane influx of extracellular calcium ions into vascular smooth muscle and cardiac muscle through L-type channels, resulting in potent peripheral arterial and coronary vasodilation with an exceptionally long half-life (30-50 hours). Indicated for essential hypertension, chronic stable angina pectoris, and vasospastic (Prinzmetal's) angina.

Recombinant Human Tissue-type Plasminogen Activator (rt-PA / Alteplase) is a fibrin-specific thrombolytic biological enzyme on the WHO Model List of Essential Medicines. It binds selectively to fibrin in a thrombus and converts trapped plasminogen into active plasmin, which cleaves fibrin matrices and dissolves the occlusive blood clot, restoring organ perfusion. Indicated for acute ischemic stroke (within 4.5 hours of symptom onset), acute ST-elevation myocardial infarction (STEMI), and massive acute pulmonary embolism with hemodynamic instability.

Recombinant Human Tissue-type Plasminogen Activator (rt-PA / Alteplase) is a fibrin-specific thrombolytic biological enzyme on the WHO Model List of Essential Medicines. It binds selectively to fibrin in a thrombus and converts trapped plasminogen into active plasmin, which cleaves fibrin matrices and dissolves the occlusive blood clot, restoring organ perfusion. Indicated for acute ischemic stroke (within 4.5 hours of symptom onset), acute ST-elevation myocardial infarction (STEMI), and massive acute pulmonary embolism with hemodynamic instability.

Caffeine Citrate is a central nervous system methylxanthine stimulant on the WHO Model List of Essential Medicines. It competitively antagonizes adenosine A1 and A2A receptors, stimulating respiratory drive in the medullary respiratory center, increasing sensitivity to hypercapnia, enhancing diaphragm contractility, and stimulating central inspiratory neuron activity. Indicated for the short-term treatment of apnea of prematurity in infants between 28 and < 33 weeks gestational age.

Bempedoic Acid is an oral, first-in-class non-statin adenosine triphosphate-citrate lyase (ACL) inhibitor. It acts upstream of HMG-CoA reductase in the hepatic cholesterol biosynthesis pathway. Because it is a prodrug requiring activation by very long-chain acyl-CoA synthetase-1 (ACSVL1), an enzyme present exclusively in the liver and absent in skeletal muscle, it inhibits cholesterol synthesis without causing the myopathy and muscle pain common to statins. Indicated for primary hyperlipidemia and to reduce cardiovascular risk in patients with atherosclerotic cardiovascular disease who are statin-intolerant.

Benazepril 5mg Tablets is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Advanced next-generation dihydropyridine calcium channel blocker (L/T-type or L/N/T-type blocker). Provides gradual, prolonged systemic vasodilation with high vascular selectivity and minimal reflex sympathetic stimulation, protecting coronary, cerebral, and renal microvasculature. Indicated for essential hypertension, renal parenchymal hypertension, and angina pectoris.

Endothelin Receptor Antagonist (ERA) on the WHO Model List of Essential Medicines. Endothelin-1 is a potent endogenous vasoconstrictor and vascular smooth muscle mitogen; ERAs selectively or dualistically block endothelin receptors (ETA and ETB) on pulmonary vascular smooth muscle, reversing pulmonary vasoconstriction, inhibiting vascular remodeling, and reducing pulmonary vascular resistance. Indicated for Pulmonary Arterial Hypertension (PAH, WHO Group 1) to improve exercise capacity and delay clinical worsening.

Nicoumalone (Acenocoumarol) 2mg Tablets is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Olmesartan Medoxomil is a potent, orally active prodrug that is rapidly de-esterified during absorption to olmesartan, a selective and insurmountable competitive antagonist at the angiotensin II AT1 receptor. It produces profound, prolonged reductions in systemic vascular resistance and blood pressure throughout the 24-hour dosing interval. Indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents (amlodipine, cilnidipine, chlorthalidone, hydrochlorothiazide).

Olmesartan Medoxomil is a potent, orally active prodrug that is rapidly de-esterified during absorption to olmesartan, a selective and insurmountable competitive antagonist at the angiotensin II AT1 receptor. It produces profound, prolonged reductions in systemic vascular resistance and blood pressure throughout the 24-hour dosing interval. Indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents (amlodipine, cilnidipine, chlorthalidone, hydrochlorothiazide).

Cilnidipine is a novel fourth-generation calcium channel blocker with unique dual L-type and N-type voltage-gated calcium channel antagonist properties. While L-type blockade dilates vascular smooth muscle, N-type blockade at sympathetic nerve terminals inhibits the pathological release of norepinephrine, suppressing sympathetic nervous hyperactivity, preventing reflex tachycardia, and dilating both afferent and efferent renal arterioles to lower intraglomerular hydrostatic pressure. Indicated for essential hypertension, particularly in patients with morning hypertension, diabetic nephropathy, chronic kidney disease, or ankle edema from amlodipine.

Cilnidipine is a novel fourth-generation calcium channel blocker with unique dual L-type and N-type voltage-gated calcium channel antagonist properties. While L-type blockade dilates vascular smooth muscle, N-type blockade at sympathetic nerve terminals inhibits the pathological release of norepinephrine, suppressing sympathetic nervous hyperactivity, preventing reflex tachycardia, and dilating both afferent and efferent renal arterioles to lower intraglomerular hydrostatic pressure. Indicated for essential hypertension, particularly in patients with morning hypertension, diabetic nephropathy, chronic kidney disease, or ankle edema from amlodipine.

Apixaban is an oral, highly selective, reversible direct factor Xa inhibitor (DOAC) on the WHO Model List of Essential Medicines. It inhibits free and clot-bound factor Xa as well as prothrombinase activity, directly decreasing thrombin generation and thrombus development without requiring antithrombin III. Does not require routine INR monitoring. Indicated for stroke prevention in non-valvular atrial fibrillation, treatment and secondary prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), and DVT prophylaxis following hip or knee arthroplasty.

Apixaban is an oral, highly selective, reversible direct factor Xa inhibitor (DOAC) on the WHO Model List of Essential Medicines. It inhibits free and clot-bound factor Xa as well as prothrombinase activity, directly decreasing thrombin generation and thrombus development without requiring antithrombin III. Does not require routine INR monitoring. Indicated for stroke prevention in non-valvular atrial fibrillation, treatment and secondary prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), and DVT prophylaxis following hip or knee arthroplasty.

Angiotensin Converting Enzyme (ACE) Inhibitor on the WHO Model List of Essential Medicines. It blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, reducing peripheral arterial resistance, decreasing aldosterone secretion, and inhibiting the enzymatic degradation of bradykinin, producing potent vasodilation and cardioprotection. Indicated for essential hypertension, heart failure with reduced ejection fraction (HFrEF), post-myocardial infarction, and diabetic nephropathy.

Statin and Fenofibrate is a comprehensive dual-action lipid-regulating combination. The statin (Atorvastatin or Rosuvastatin) competitively inhibits HMG-CoA reductase, potently lowering LDL cholesterol and apolipoprotein B, while fenofibrate, a fibric acid derivative, activates peroxisome proliferator-activated receptor-alpha (PPAR-alpha), dramatically reducing triglycerides (by 30-50%), increasing HDL cholesterol, and converting atherogenic small dense LDL into larger buoyant particles. Indicated for mixed dyslipidemia, severe hypertriglyceridemia, and diabetic dyslipidemia.

Statin and Ezetimibe is an intensive dual-pathway LDL-lowering formulation. The statin inhibits endogenous cholesterol biosynthesis in the liver, while ezetimibe selectively inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the intestinal brush border, blocking absorption of dietary and biliary cholesterol. This dual mechanism achieves up to 65% reduction in LDL cholesterol without requiring high-dose statin monotherapy. Indicated for primary hyperlipidemia, familial hypercholesterolemia, and high-risk atherosclerotic cardiovascular disease.

Statin and Ezetimibe is an intensive dual-pathway LDL-lowering formulation. The statin inhibits endogenous cholesterol biosynthesis in the liver, while ezetimibe selectively inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the intestinal brush border, blocking absorption of dietary and biliary cholesterol. This dual mechanism achieves up to 65% reduction in LDL cholesterol without requiring high-dose statin monotherapy. Indicated for primary hyperlipidemia, familial hypercholesterolemia, and high-risk atherosclerotic cardiovascular disease.

Advanced next-generation dihydropyridine calcium channel blocker (L/T-type or L/N/T-type blocker). Provides gradual, prolonged systemic vasodilation with high vascular selectivity and minimal reflex sympathetic stimulation, protecting coronary, cerebral, and renal microvasculature. Indicated for essential hypertension, renal parenchymal hypertension, and angina pectoris.

Telmisartan is a potent, non-peptide, long-acting angiotensin II type 1 (AT1) receptor antagonist on the WHO Model List of Essential Medicines. It exhibits an exceptionally long elimination half-life (around 24 hours) providing sustained 24-hour blood pressure control with high trough-to-peak ratio, and uniquely functions as a partial agonist at peroxisome proliferator-activated receptor-gamma (PPAR-gamma), improving glucose handling and lipid metabolism. Indicated for essential hypertension and cardiovascular risk reduction in patients with coronary artery disease, stroke, or diabetes with end-organ damage.

Advanced next-generation dihydropyridine calcium channel blocker (L/T-type or L/N/T-type blocker). Provides gradual, prolonged systemic vasodilation with high vascular selectivity and minimal reflex sympathetic stimulation, protecting coronary, cerebral, and renal microvasculature. Indicated for essential hypertension, renal parenchymal hypertension, and angina pectoris.

Telmisartan and Chlorthalidone is a potent, long-acting dual antihypertensive combination. Telmisartan delivers selective 24-hour AT1 receptor blockade, while chlorthalidone, a long-acting monosulfonamyl thiazide-like diuretic with a terminal elimination half-life of 40-60 hours, provides sustained intravascular volume and vascular resistance reduction throughout day and night. Indicated for stage 2 hypertension and nocturnal/early morning hypertension surges.

Clopidogrel Bisulphate is an oral thienopyridine P2Y12 platelet inhibitor on the WHO Model List of Essential Medicines. It requires hepatic bioactivation by CYP2C19 to form an active thiol metabolite that irreversibly modifies platelet P2Y12 ADP receptors for the entire 7-10 day lifespan of the platelet, preventing ADP-induced platelet activation and fibrinogen binding. Indicated for secondary prevention of atherothrombotic events in patients with recent myocardial infarction, recent ischemic stroke, or established peripheral arterial disease, and as part of DAPT in acute coronary syndromes.

Ezetimibe Tablets 10mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Ezetimibe Tablets 5mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Endothelin Receptor Antagonist (ERA) on the WHO Model List of Essential Medicines. Endothelin-1 is a potent endogenous vasoconstrictor and vascular smooth muscle mitogen; ERAs selectively or dualistically block endothelin receptors (ETA and ETB) on pulmonary vascular smooth muscle, reversing pulmonary vasoconstriction, inhibiting vascular remodeling, and reducing pulmonary vascular resistance. Indicated for Pulmonary Arterial Hypertension (PAH, WHO Group 1) to improve exercise capacity and delay clinical worsening.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Midodrine Hydrochloride is an oral prodrug that is enzymatically hydrolyzed by systemic deglycination to desglymidodrine, a potent, selective, peripherally-acting alpha-1 adrenergic receptor agonist. It acts directly on alpha-1 receptors of arteriolar and venous vasculature to increase vascular tone and total peripheral resistance, elevating systolic and diastolic blood pressure and reducing venous pooling. Indicated for the treatment of symptomatic orthostatic hypotension in patients whose lives are considerably impaired despite standard clinical care.

Midodrine Hydrochloride is an oral prodrug that is enzymatically hydrolyzed by systemic deglycination to desglymidodrine, a potent, selective, peripherally-acting alpha-1 adrenergic receptor agonist. It acts directly on alpha-1 receptors of arteriolar and venous vasculature to increase vascular tone and total peripheral resistance, elevating systolic and diastolic blood pressure and reducing venous pooling. Indicated for the treatment of symptomatic orthostatic hypotension in patients whose lives are considerably impaired despite standard clinical care.

Midodrine Hydrochloride is an oral prodrug that is enzymatically hydrolyzed by systemic deglycination to desglymidodrine, a potent, selective, peripherally-acting alpha-1 adrenergic receptor agonist. It acts directly on alpha-1 receptors of arteriolar and venous vasculature to increase vascular tone and total peripheral resistance, elevating systolic and diastolic blood pressure and reducing venous pooling. Indicated for the treatment of symptomatic orthostatic hypotension in patients whose lives are considerably impaired despite standard clinical care.

Amlodipine (or S-Amlodipine, the pure chirally active enantiomer with lower incidence of ankle edema) is a third-generation dihydropyridine calcium channel blocker on the WHO Model List of Essential Medicines. It inhibits transmembrane influx of extracellular calcium ions into vascular smooth muscle and cardiac muscle through L-type channels, resulting in potent peripheral arterial and coronary vasodilation with an exceptionally long half-life (30-50 hours). Indicated for essential hypertension, chronic stable angina pectoris, and vasospastic (Prinzmetal's) angina.

Amlodipine (or S-Amlodipine, the pure chirally active enantiomer with lower incidence of ankle edema) is a third-generation dihydropyridine calcium channel blocker on the WHO Model List of Essential Medicines. It inhibits transmembrane influx of extracellular calcium ions into vascular smooth muscle and cardiac muscle through L-type channels, resulting in potent peripheral arterial and coronary vasodilation with an exceptionally long half-life (30-50 hours). Indicated for essential hypertension, chronic stable angina pectoris, and vasospastic (Prinzmetal's) angina.

Olmesartan Medoxomil is a potent, orally active prodrug that is rapidly de-esterified during absorption to olmesartan, a selective and insurmountable competitive antagonist at the angiotensin II AT1 receptor. It produces profound, prolonged reductions in systemic vascular resistance and blood pressure throughout the 24-hour dosing interval. Indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents (amlodipine, cilnidipine, chlorthalidone, hydrochlorothiazide).

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Angiotensin Converting Enzyme (ACE) Inhibitor on the WHO Model List of Essential Medicines. It blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, reducing peripheral arterial resistance, decreasing aldosterone secretion, and inhibiting the enzymatic degradation of bradykinin, producing potent vasodilation and cardioprotection. Indicated for essential hypertension, heart failure with reduced ejection fraction (HFrEF), post-myocardial infarction, and diabetic nephropathy.

Angiotensin Converting Enzyme (ACE) Inhibitor on the WHO Model List of Essential Medicines. It blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, reducing peripheral arterial resistance, decreasing aldosterone secretion, and inhibiting the enzymatic degradation of bradykinin, producing potent vasodilation and cardioprotection. Indicated for essential hypertension, heart failure with reduced ejection fraction (HFrEF), post-myocardial infarction, and diabetic nephropathy.

Telmisartan and Cilnidipine is an innovative vascular- and renal-protective antihypertensive combination. Telmisartan blocks AT1 angiotensin receptors, while cilnidipine acts as a unique dual L-type and N-type voltage-gated calcium channel blocker. Blockade of sympathetic N-type calcium channels on sympathetic nerve endings inhibits excessive norepinephrine release, preventing reflex tachycardia and dilating both efferent and afferent renal arterioles, which lowers intraglomerular pressure and reduces proteinuria with virtually zero incidence of pedal edema. Indicated for essential hypertension, particularly in patients with metabolic syndrome, diabetes, or renal impairment.

Telmisartan and Cilnidipine is an innovative vascular- and renal-protective antihypertensive combination. Telmisartan blocks AT1 angiotensin receptors, while cilnidipine acts as a unique dual L-type and N-type voltage-gated calcium channel blocker. Blockade of sympathetic N-type calcium channels on sympathetic nerve endings inhibits excessive norepinephrine release, preventing reflex tachycardia and dilating both efferent and afferent renal arterioles, which lowers intraglomerular pressure and reduces proteinuria with virtually zero incidence of pedal edema. Indicated for essential hypertension, particularly in patients with metabolic syndrome, diabetes, or renal impairment.

Telmisartan and Metoprolol Succinate (Extended-Release) combines an ARB with a cardioselective beta-1 adrenergic blocker. Telmisartan reduces afterload and inhibits vascular remodeling, while extended-release metoprolol attenuates sympathetic nervous activity, reduces resting and exercise heart rates, lowers myocardial oxygen demand, and stabilizes cardiac rhythm. Indicated for hypertension associated with coronary artery disease, stable angina, post-myocardial infarction, or resting tachycardia.

Ticagrelor is a direct-acting, reversibly-binding cyclopentyltriazolopyrimidine P2Y12 platelet antagonist on the WHO Model List of Essential Medicines. Unlike thienopyridines (clopidogrel, prasugrel), it does not require metabolic bioactivation, offering rapid, predictable, and reversible platelet inhibition. Indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS) or a history of myocardial infarction and high risk of developing an atherothrombotic event.

Amlodipine (or S-Amlodipine, the pure chirally active enantiomer with lower incidence of ankle edema) is a third-generation dihydropyridine calcium channel blocker on the WHO Model List of Essential Medicines. It inhibits transmembrane influx of extracellular calcium ions into vascular smooth muscle and cardiac muscle through L-type channels, resulting in potent peripheral arterial and coronary vasodilation with an exceptionally long half-life (30-50 hours). Indicated for essential hypertension, chronic stable angina pectoris, and vasospastic (Prinzmetal's) angina.

Amlodipine (or S-Amlodipine, the pure chirally active enantiomer with lower incidence of ankle edema) is a third-generation dihydropyridine calcium channel blocker on the WHO Model List of Essential Medicines. It inhibits transmembrane influx of extracellular calcium ions into vascular smooth muscle and cardiac muscle through L-type channels, resulting in potent peripheral arterial and coronary vasodilation with an exceptionally long half-life (30-50 hours). Indicated for essential hypertension, chronic stable angina pectoris, and vasospastic (Prinzmetal's) angina.

Statin and Antiplatelet (Aspirin +/- Clopidogrel) cardiovascular polypill formulation. Unites intensive lipid lowering and plaque stabilization (via HMG-CoA reductase inhibition) with antiplatelet thrombus prevention (via irreversible COX-1 inhibition and/or ADP P2Y12 platelet receptor blockade). Indicated for secondary prevention in coronary artery disease, acute coronary syndrome, post-percutaneous coronary intervention (PCI/stenting), and ischemic stroke.

Telmisartan and Chlorthalidone is a potent, long-acting dual antihypertensive combination. Telmisartan delivers selective 24-hour AT1 receptor blockade, while chlorthalidone, a long-acting monosulfonamyl thiazide-like diuretic with a terminal elimination half-life of 40-60 hours, provides sustained intravascular volume and vascular resistance reduction throughout day and night. Indicated for stage 2 hypertension and nocturnal/early morning hypertension surges.

Endothelin Receptor Antagonist (ERA) on the WHO Model List of Essential Medicines. Endothelin-1 is a potent endogenous vasoconstrictor and vascular smooth muscle mitogen; ERAs selectively or dualistically block endothelin receptors (ETA and ETB) on pulmonary vascular smooth muscle, reversing pulmonary vasoconstriction, inhibiting vascular remodeling, and reducing pulmonary vascular resistance. Indicated for Pulmonary Arterial Hypertension (PAH, WHO Group 1) to improve exercise capacity and delay clinical worsening.

Endothelin Receptor Antagonist (ERA) on the WHO Model List of Essential Medicines. Endothelin-1 is a potent endogenous vasoconstrictor and vascular smooth muscle mitogen; ERAs selectively or dualistically block endothelin receptors (ETA and ETB) on pulmonary vascular smooth muscle, reversing pulmonary vasoconstriction, inhibiting vascular remodeling, and reducing pulmonary vascular resistance. Indicated for Pulmonary Arterial Hypertension (PAH, WHO Group 1) to improve exercise capacity and delay clinical worsening.

Azilsartan Medoxomil Tablets 20mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Azilsartan Medoxomil Tablets 80mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Endothelin Receptor Antagonist (ERA) on the WHO Model List of Essential Medicines. Endothelin-1 is a potent endogenous vasoconstrictor and vascular smooth muscle mitogen; ERAs selectively or dualistically block endothelin receptors (ETA and ETB) on pulmonary vascular smooth muscle, reversing pulmonary vasoconstriction, inhibiting vascular remodeling, and reducing pulmonary vascular resistance. Indicated for Pulmonary Arterial Hypertension (PAH, WHO Group 1) to improve exercise capacity and delay clinical worsening.

Advanced next-generation dihydropyridine calcium channel blocker (L/T-type or L/N/T-type blocker). Provides gradual, prolonged systemic vasodilation with high vascular selectivity and minimal reflex sympathetic stimulation, protecting coronary, cerebral, and renal microvasculature. Indicated for essential hypertension, renal parenchymal hypertension, and angina pectoris.

Advanced next-generation dihydropyridine calcium channel blocker (L/T-type or L/N/T-type blocker). Provides gradual, prolonged systemic vasodilation with high vascular selectivity and minimal reflex sympathetic stimulation, protecting coronary, cerebral, and renal microvasculature. Indicated for essential hypertension, renal parenchymal hypertension, and angina pectoris.

Eplerenone 50mg Tablets is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Selexipag is an orally active, selective, non-prostanoid prostacyclin (IP) receptor agonist on the WHO Model List of Essential Medicines. It is hydrolyzed by carboxylesterase 1 into an active metabolite with 37-fold higher potency. Stimulation of the IP receptor activates adenylyl cyclase, elevating intracellular cyclic AMP and producing potent pulmonary vasodilation and anti-proliferative effects. Indicated for the long-term treatment of Pulmonary Arterial Hypertension (PAH, WHO Group 1) to delay disease progression and reduce hospitalization.

Selexipag is an orally active, selective, non-prostanoid prostacyclin (IP) receptor agonist on the WHO Model List of Essential Medicines. It is hydrolyzed by carboxylesterase 1 into an active metabolite with 37-fold higher potency. Stimulation of the IP receptor activates adenylyl cyclase, elevating intracellular cyclic AMP and producing potent pulmonary vasodilation and anti-proliferative effects. Indicated for the long-term treatment of Pulmonary Arterial Hypertension (PAH, WHO Group 1) to delay disease progression and reduce hospitalization.

Sildenafil Tablets 20mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Telmisartan is a potent, non-peptide, long-acting angiotensin II type 1 (AT1) receptor antagonist on the WHO Model List of Essential Medicines. It exhibits an exceptionally long elimination half-life (around 24 hours) providing sustained 24-hour blood pressure control with high trough-to-peak ratio, and uniquely functions as a partial agonist at peroxisome proliferator-activated receptor-gamma (PPAR-gamma), improving glucose handling and lipid metabolism. Indicated for essential hypertension and cardiovascular risk reduction in patients with coronary artery disease, stroke, or diabetes with end-organ damage.

Telmisartan is a potent, non-peptide, long-acting angiotensin II type 1 (AT1) receptor antagonist on the WHO Model List of Essential Medicines. It exhibits an exceptionally long elimination half-life (around 24 hours) providing sustained 24-hour blood pressure control with high trough-to-peak ratio, and uniquely functions as a partial agonist at peroxisome proliferator-activated receptor-gamma (PPAR-gamma), improving glucose handling and lipid metabolism. Indicated for essential hypertension and cardiovascular risk reduction in patients with coronary artery disease, stroke, or diabetes with end-organ damage.

Hydrochlorothiazide Tablets 25 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Nifedipine Extended Release Tablets 30 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Nifedipine Extended Release Tablets 60 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Olmesartan Medoxomil is a potent, orally active prodrug that is rapidly de-esterified during absorption to olmesartan, a selective and insurmountable competitive antagonist at the angiotensin II AT1 receptor. It produces profound, prolonged reductions in systemic vascular resistance and blood pressure throughout the 24-hour dosing interval. Indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents (amlodipine, cilnidipine, chlorthalidone, hydrochlorothiazide).

Olmesartan Medoxomil is a potent, orally active prodrug that is rapidly de-esterified during absorption to olmesartan, a selective and insurmountable competitive antagonist at the angiotensin II AT1 receptor. It produces profound, prolonged reductions in systemic vascular resistance and blood pressure throughout the 24-hour dosing interval. Indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents (amlodipine, cilnidipine, chlorthalidone, hydrochlorothiazide).

Olmesartan Medoxomil is a potent, orally active prodrug that is rapidly de-esterified during absorption to olmesartan, a selective and insurmountable competitive antagonist at the angiotensin II AT1 receptor. It produces profound, prolonged reductions in systemic vascular resistance and blood pressure throughout the 24-hour dosing interval. Indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents (amlodipine, cilnidipine, chlorthalidone, hydrochlorothiazide).

Olmesartan Medoxomil is a potent, orally active prodrug that is rapidly de-esterified during absorption to olmesartan, a selective and insurmountable competitive antagonist at the angiotensin II AT1 receptor. It produces profound, prolonged reductions in systemic vascular resistance and blood pressure throughout the 24-hour dosing interval. Indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents (amlodipine, cilnidipine, chlorthalidone, hydrochlorothiazide).

Rivaroxaban is an oral, direct, and selective competitive factor Xa inhibitor (DOAC) on the WHO Model List of Essential Medicines. By blocking factor Xa, it interrupts both intrinsic and extrinsic coagulation cascades, preventing thrombin generation and clot propagation. Indicated for stroke prevention in non-valvular atrial fibrillation, treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), and CAD/PAD risk reduction (in combination with aspirin).

Rivaroxaban is an oral, direct, and selective competitive factor Xa inhibitor (DOAC) on the WHO Model List of Essential Medicines. By blocking factor Xa, it interrupts both intrinsic and extrinsic coagulation cascades, preventing thrombin generation and clot propagation. Indicated for stroke prevention in non-valvular atrial fibrillation, treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), and CAD/PAD risk reduction (in combination with aspirin).

Romiplostim is a recombinant thrombopoietin (TPO) receptor agonist "peptibody." It binds to and activates the human TPO receptor (c-Mpl) on megakaryocytes and hematopoietic stem cells via the JAK/STAT pathway, stimulating megakaryocyte proliferation and platelet production. Indicated for immune thrombocytopenia (ITP) in adults refractory to corticosteroids, immunoglobulins, or splenectomy.

Romiplostim is a recombinant thrombopoietin (TPO) receptor agonist "peptibody." It binds to and activates the human TPO receptor (c-Mpl) on megakaryocytes and hematopoietic stem cells via the JAK/STAT pathway, stimulating megakaryocyte proliferation and platelet production. Indicated for immune thrombocytopenia (ITP) in adults refractory to corticosteroids, immunoglobulins, or splenectomy.

Spironolactone is a synthetic steroid competitive mineralocorticoid receptor (aldosterone) antagonist and potassium-sparing diuretic on the WHO Model List of Essential Medicines. It blocks aldosterone binding in the late distal renal tubules and cortical collecting ducts, increasing sodium and water excretion while conserving potassium and hydrogen ions. In heart failure, it blocks aldosterone-mediated myocardial fibrosis and endothelial dysfunction. Indicated for heart failure with reduced ejection fraction (NYHA class II-IV), primary hyperaldosteronism, cirrhosis with ascites, resistant hypertension, and nephrotic edema.

Spironolactone is a synthetic steroid competitive mineralocorticoid receptor (aldosterone) antagonist and potassium-sparing diuretic on the WHO Model List of Essential Medicines. It blocks aldosterone binding in the late distal renal tubules and cortical collecting ducts, increasing sodium and water excretion while conserving potassium and hydrogen ions. In heart failure, it blocks aldosterone-mediated myocardial fibrosis and endothelial dysfunction. Indicated for heart failure with reduced ejection fraction (NYHA class II-IV), primary hyperaldosteronism, cirrhosis with ascites, resistant hypertension, and nephrotic edema.

Spironolactone is a synthetic steroid competitive mineralocorticoid receptor (aldosterone) antagonist and potassium-sparing diuretic on the WHO Model List of Essential Medicines. It blocks aldosterone binding in the late distal renal tubules and cortical collecting ducts, increasing sodium and water excretion while conserving potassium and hydrogen ions. In heart failure, it blocks aldosterone-mediated myocardial fibrosis and endothelial dysfunction. Indicated for heart failure with reduced ejection fraction (NYHA class II-IV), primary hyperaldosteronism, cirrhosis with ascites, resistant hypertension, and nephrotic edema.

Spironolactone is a synthetic steroid competitive mineralocorticoid receptor (aldosterone) antagonist and potassium-sparing diuretic on the WHO Model List of Essential Medicines. It blocks aldosterone binding in the late distal renal tubules and cortical collecting ducts, increasing sodium and water excretion while conserving potassium and hydrogen ions. In heart failure, it blocks aldosterone-mediated myocardial fibrosis and endothelial dysfunction. Indicated for heart failure with reduced ejection fraction (NYHA class II-IV), primary hyperaldosteronism, cirrhosis with ascites, resistant hypertension, and nephrotic edema.

Amlodipine (or S-Amlodipine, the pure chirally active enantiomer with lower incidence of ankle edema) is a third-generation dihydropyridine calcium channel blocker on the WHO Model List of Essential Medicines. It inhibits transmembrane influx of extracellular calcium ions into vascular smooth muscle and cardiac muscle through L-type channels, resulting in potent peripheral arterial and coronary vasodilation with an exceptionally long half-life (30-50 hours). Indicated for essential hypertension, chronic stable angina pectoris, and vasospastic (Prinzmetal's) angina.

Amlodipine (or S-Amlodipine, the pure chirally active enantiomer with lower incidence of ankle edema) is a third-generation dihydropyridine calcium channel blocker on the WHO Model List of Essential Medicines. It inhibits transmembrane influx of extracellular calcium ions into vascular smooth muscle and cardiac muscle through L-type channels, resulting in potent peripheral arterial and coronary vasodilation with an exceptionally long half-life (30-50 hours). Indicated for essential hypertension, chronic stable angina pectoris, and vasospastic (Prinzmetal's) angina.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Losartan Potassium is the prototype selective competitive angiotensin II receptor type 1 (AT1) antagonist on the WHO Model List of Essential Medicines. It blocks the physiological actions of angiotensin II, lowering systemic vascular resistance and aldosterone secretion, while its active metabolite EXP3174 provides long-acting non-competitive blockade. Possesses unique uricosuric activity, lowering serum uric acid levels. Indicated for essential hypertension, diabetic nephropathy in type 2 diabetes with elevated creatinine and proteinuria, and stroke reduction in hypertensive patients with left ventricular hypertrophy.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.